Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070965 · ClinicalTrials.gov registry record · Phase 2
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
A Phase 2 study, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT02070965: Completed Phase 2 study, sponsored by Primus Pharmaceuticals.
NCT02070965 is a Phase 2 study that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02070965, a Phase 2 study, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
Interventions
- DRUG DFD01 Spray
- DRUG Comp01 Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
What the finished NCT02070965 record still lists
NCT02070965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 2 interventions - of which DFD01 Spray is the first listed.
NCT02070965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02070965 about?
NCT02070965 is a clinical study titled "DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
What is the current status of trial NCT02070965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2014-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02070965?
The interventions under investigation include: DFD01 Spray (DRUG), Comp01 Lotion (DRUG).
Who is sponsoring clinical trial NCT02070965?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02070965's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia